Biomarin raises Voxzogo sales expectations again

US-based Biomarin has recently launched its dwarfism drug Voxzogo, and the company is now increasing its sales expectations for the drug for the second time.

Photo: Anders Rye Skjoldjensen

When Biomarin released its full-year report for 2021, the company also increased its sales expectations for Voxzogo, a treatment for achondroplasia, also known as dwarfism.

One quarter into 2022, Biomarin is pulling the same move again, raising the drug’s sales outlook for 2022 to USD 100-125m from a previous USD 90-115m, according to the company’s recently publicized Q1 report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs